has shifted to using neural and mesenchymal stem cells in stroke, not as agents for cell replacement, but rather as immunomodulators intended to suppress the post-ischemic inflammatory response (Aharonowiz et al., 2008; Kokaia et al., 2012). This is an approach that may yet prove promising, but that should not be confused with cell replacement for structural repair.
